- Published at
- by manilatimes.net
positive
positive
News for Pharming Group N.V. (PHARM.AS)
- Published at
- by manilatimes.net
positivepositive- Published at
- by manilatimes.net
positivepositive- Published at
- by seekingalpha.com
positivepositivePharming Group N.V. (PHAR) Q4 2024 Earnings Call Transcript
Pharming Group N.V. (NASDAQ:PHAR) Q4 2024 Earnings Conference Call March 13, 2025 8:30 AM ETCompany ParticipantsFabrice Chouraqui - CEOStephen Toor -...- Published at
- by benzinga.com
mixedmixedG-III Apparel Posts Better-Than-Expected Earnings, Joins Ballard Power Systems, Dollar General And Other Big Stocks Moving Higher On Thursday - Advantage Solutions (NASDAQ:ADV), AES (NYSE:AES)
U.S. stocks were lower, with the Dow Jones index falling around 100 points on Thursday. Shares of G-III Apparel Group, Ltd. GIII gained 13.9% to $28.87 after t...- Published at
- by manilatimes.net
neutralneutral- Published at
- by manilatimes.net
positivepositive- Published at
- by manilatimes.net
neutralneutral- Published at
- by manilatimes.net
mixedmixed- Published at
- by manilatimes.net
positivepositive- Published at
- by manilatimes.net
positivepositive- Published at
- by manilatimes.net
positivepositive- Published at
- by manilatimes.net
mixedmixed- Published at
- by manilatimes.net
positivepositive- Published at
- by manilatimes.net
positivepositive- Published at
- by manilatimes.net
mixedmixed- Published at
- by globenewswire.com
mixedmixedPharming Group reports third quarter 2024 financial results and provides business update
Third quarter 2024 total revenues increased by 12% to US$74.8 million, compared to the third quarter 2023, driven by continued strong RUCONEST® and Joenja®...- Published at
- by globenewswire.com
neutralneutralPharming Group to report third quarter 2024 financial results on October 24
Leiden, the Netherlands, October 10, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its...- Published at
- by globenewswire.com
positivepositivePharming Group announces start of Phase II clinical trial of leniolisib for primary immunodeficiencies (PIDs) with immune dysregulation
Proof of concept clinical trial will evaluate leniolisib in PIDs with immune dysregulation linked to altered PI3Kẟ signaling in lymphocytes PIDs to...- Published at
- by globenewswire.com
positivepositivePharming announces marketing authorization in the U.K. for Joenja® (leniolisib)
For media and investors only Indicated for adult and pediatric patients 12 years of age and older with activated phosphoinositide 3-kinase delta...